ACTRN12613000270718已完成未知
A multicentre phase II randomised controlled trial of a parent/carer-targeted intervention to improve quality of life in families of young cancer survivors.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Eligible participants will be parents/carers of children who are <18 years old and have finished cancer treatment with curative intent. Parents will be (1) Fluent in English; (2) Able to access the internet; (3) Not at risk of self-harm/psychosis (assessed during the initial clinical screen). Only one parent/carer from each family will be eligible to minimise clinical/logistical challenges. Parents of children who have previously relapsed (and are finished treatment with curative intent) will be eligible. However, if a child relapses or dies during the study, their parents will be referred to individual support.
排除标准
- •Individuals may not participate if they
- •(1) cannot speak English;
- •(2) exhibit suicidal intent, psychotic features, or substance dependence;
- •(3) their child is receiving active treatment, or palliative care. This includes if a child has recently relapsed and is still in active treatment; they and their family will be excluded, as their needs will be difficult to manage within the protocol, and their inclusion might also negatively affect others in their group.
研究者
相似试验
进行中（未招募）
1 期
A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magnetic resonance imaging (MRI) defined high risk rectal cancer. - EXPERT-CHigh risk operable rectal adenocarcinomaMedDRA version: 13.1 Level: PT Classification code 10038038 Term: Rectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2004-004707-38-GBRoyal Marsden NHS Trust164
已完成
不适用
A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magentic resonance imaging defined high risk rectal cancerRectal cancerCancerISRCTN99828560Royal Marsden NHS Foundation Trust (UK)164
进行中（未招募）
不适用
A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magnetic resonance imaging (MRI) defined poor risk rectal cancer. - EXPERT-CPoor risk operable rectal adenocarcinomaEUCTR2004-004707-38-SEProf David Cunningham164
尚未招募
不适用
Evaluating the efficacy of radiation therapy compared to surveillance in men with prostate cancer that has returned after surgery and negative Prostate specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) scan.Cancer - ProstateProstate cancerACTRN12622001478707The Australian and New Zealand Urogenital and Prostate Cancer Trials Group Ltd100
进行中（未招募）
1 期
A trial testing a new agent for patients with diffuse large B cell lymphoma (DLBCL) who have heart conditions and unable to receive standard treatmentDiffuse large B cell lymphomaMedDRA version: 21.0 Level: PT Classification code 10012818 Term: Diffuse large B-cell lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001900-39-GBniversity College London132